You can buy or sell ATRA and other stocks, options, ETFs, and crypto commission-free!
Atara Biotherapeutics, Inc. operates as a clinical stage company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Its product candidates are biologics targeting myostatin and activin, members of the transforming growth factor-beta, protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. Read More The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
South San Francisco, California
52 Week High
52 Week Low
Seeking AlphaMay 13
Atara Biotherapeutics: T-Cell Therapy Developer With Late-Stage Candidate In Rare Disease
Atara Biotherapeutics (ATRA) is an allogenic, off-the-shelf T-cell therapy developer with a late-stage pipeline targeting post-transplant lymphoproliferative disorder (EBV+PTLD) associated with Epstein-Barr Virus as its lead indication, with a slew of further indications backing it up.
Yahoo FinanceMay 9
Atara Biotherapeutics: 1Q Earnings Snapshot
SOUTH SAN FRANCISCO, Calif. (AP) _ Atara Biotherapeutics Inc. (ATRA) on Thursday reported a loss of $66.3 million in its first quarter. The South San Francisco, California-based company said it had a loss of $1.44 per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of $1.48 per share. Atara Biotherapeutics shares have decreased slightly more than 1% since the beginning of the year. The stock has declined 13%...
Expected Jul 31, Pre-Market